1. Home
  2. TBLA vs TYRA Comparison

TBLA vs TYRA Comparison

Compare TBLA & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Taboola.com Ltd.

TBLA

Taboola.com Ltd.

HOLD

Current Price

$3.15

Market Cap

1.1B

Sector

Technology

ML Signal

HOLD

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

HOLD

Current Price

$36.61

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBLA
TYRA
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TBLA
TYRA
Price
$3.15
$36.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
9
Target Price
$5.00
$46.38
AVG Volume (30 Days)
2.2M
1.2M
Earning Date
05-06-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$7.63
N/A
Revenue Next Year
$5.25
N/A
P/E Ratio
$42.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.63
$6.42
52 Week High
$4.65
$39.15

Technical Indicators

Market Signals
Indicator
TBLA
TYRA
Relative Strength Index (RSI) 43.45 59.63
Support Level $3.13 $30.10
Resistance Level $3.50 N/A
Average True Range (ATR) 0.14 2.34
MACD 0.02 0.03
Stochastic Oscillator 24.42 70.74

Price Performance

Historical Comparison
TBLA
TYRA

About TBLA Taboola.com Ltd.

Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are TYRA-300, TYRA-200, and TYRA-430: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: